AKBA
Akebia Therapeutics Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 03-25-2019 after market close | 03-25-2019 after market close | 03-25-2019 after market close | 11-08-2018 | 08-08-2018 after market close | 05-09-2018 | 03-12-2018 after market close | 11-08-2017 | 08-08-2017 | 05-09-2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Actual EPS | -0.91 | -0.91 | -0.91 | -0.46 | -0.6 | -0.48 | 0.25 | -0.49 | -0.53 | -1.15 |
| Consensus EPS | -0.27 | -0.27 | -0.27 | -0.77 | -0.52 | -0.55 | -0.18 | -0.7 | -0.82 | -0.56 |
| Estimated EPS | -0.27 | -0.27 | -0.27 | -0.77 | -0.52 | -0.55 | -0.18 | -0.7 | -0.82 | -0.56 |
| Number of Estimates | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 |
| EPS Surprise | -$0.64 | -$0.64 | -$0.64 | $0.31 | -$0.08 | $0.07 | $0.43 | $0.21 | $0.29 | -$0.59 |
Stats
Summary
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.
Market Cap: 716 Million
Primary Exchange: NASDAQ Global Market
Website: http://www.akebia.com
Shares Outstanding: 47.3 Million
Float: 46.3 Million
Dividend: 0.0 (0.0%)
Beta: 0.800416
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 3.35 Million
Ethical Flags
Longest drawdown: 1767 trading days
From: 2014-06-20 To: 2019-06-12
Lowest Point:
Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease
via: Business Wire at 2019-06-11 03:30:00:000
AkebiaCares connects patients, caregivers and health care providers with resources and important information to support greater access to therapy Akebia Therapeutics, Inc. (Nasdaq: AKBA) a biopharmaceutical company focused on the development and commercialization of therapeutics for… read more...
Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease
via: Business Wire at 2019-06-11 03:30:00:000
AkebiaCares connects patients, caregivers and health care providers with resources and important information to support greater access to therapy Akebia Therapeutics, Inc. (Nasdaq: AKBA) a biopharmaceutical company focused on the development and commercialization of therapeutics for… read more...
Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease
via: Business Wire at 2019-06-11 03:30:00:000
AkebiaCares connects patients, caregivers and health care providers with resources and important information to support greater access to therapy Akebia Therapeutics, Inc. (Nasdaq: AKBA) a biopharmaceutical company focused on the development and commercialization of therapeutics for… read more...
Akebia Therapeutics (AKBA) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-06-05 08:32:57:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia Therapeutics (AKBA) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-06-05 08:32:57:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia Therapeutics (AKBA) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-06-05 08:32:57:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia Therapeutics (AKBA) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-06-05 08:32:57:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia Therapeutics (AKBA) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-06-05 08:32:57:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia Therapeutics (AKBA) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-06-05 08:32:57:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-06-04 12:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 14 newly-hired employees options to purchase an aggregate of 344,200 shares of Akebias common stock on Ma… read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2019-05-29 04:00:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer of Akebia, will participate in the following i… read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2019-05-29 04:00:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer of Akebia, will participate in the following i… read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2019-05-29 04:00:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer of Akebia, will participate in the following i… read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2019-05-29 04:00:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer of Akebia, will participate in the following i… read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2019-05-29 04:00:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer of Akebia, will participate in the following i… read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2019-05-29 04:00:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer of Akebia, will participate in the following i… read more...
Aerpio Pharmaceuticals: Eye Spy An Opportunity
via: SeekingAlpha at 2019-05-22 11:00:00:000
According to Aerpio Pharmaceuticals (ARPO) website, they are a bio pharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Personally, I think the description is far too narrow and base my opinion on both the company's recent strong secondary readouts from … read more...
Aerpio Pharmaceuticals: Eye Spy An Opportunity
via: SeekingAlpha at 2019-05-22 11:00:00:000
According to Aerpio Pharmaceuticals (ARPO) website, they are a bio pharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Personally, I think the description is far too narrow and base my opinion on both the company's recent strong secondary readouts from … read more...
Aerpio Pharmaceuticals: Eye Spy An Opportunity
via: SeekingAlpha at 2019-05-22 11:00:00:000
According to Aerpio Pharmaceuticals (ARPO) website, they are a bio pharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Personally, I think the description is far too narrow and base my opinion on both the company's recent strong secondary readouts from … read more...
Aerpio Pharmaceuticals: Eye Spy An Opportunity
via: SeekingAlpha at 2019-05-22 11:00:00:000
According to Aerpio Pharmaceuticals (ARPO) website, they are a bio pharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Personally, I think the description is far too narrow and base my opinion on both the company's recent strong secondary readouts from … read more...
Aerpio Pharmaceuticals: Eye Spy An Opportunity
via: SeekingAlpha at 2019-05-22 11:00:00:000
According to Aerpio Pharmaceuticals (ARPO) website, they are a bio pharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Personally, I think the description is far too narrow and base my opinion on both the company's recent strong secondary readouts from … read more...
Aerpio Pharmaceuticals: Eye Spy An Opportunity
via: SeekingAlpha at 2019-05-22 11:00:00:000
According to Aerpio Pharmaceuticals (ARPO) website, they are a bio pharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Personally, I think the description is far too narrow and base my opinion on both the company's recent strong secondary readouts from … read more...
Aerpio Pharmaceuticals: Eye Spy An Opportunity
via: SeekingAlpha at 2019-05-22 11:00:00:000
According to Aerpio Pharmaceuticals (ARPO) website, they are a bio pharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Personally, I think the description is far too narrow and base my opinion on both the company's recent strong secondary readouts from … read more...
Tracking Seth Klarman's Baupost Group Holdings - Q1 2019 Update
via: SeekingAlpha at 2019-05-17 23:28:37:000
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a… read more...
Tracking Seth Klarman's Baupost Group Holdings - Q1 2019 Update
via: SeekingAlpha at 2019-05-17 23:28:37:000
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a… read more...
Tracking Seth Klarman's Baupost Group Holdings - Q1 2019 Update
via: SeekingAlpha at 2019-05-17 23:28:37:000
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a… read more...
Tracking Seth Klarman's Baupost Group Holdings - Q1 2019 Update
via: SeekingAlpha at 2019-05-17 23:28:37:000
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a… read more...
Tracking David Abrams' Abrams Capital Management Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-05-13 00:53:45:000
This article is part of a series that provides an ongoing analysis of the changes made to David Abrams 13F portfolio on a quarterly basis. It is based on Abrams regulatory 13F Form filed on 05/10/2019. Please visit our Tracking David Abrams Abrams Capital Management … read more...
Tracking David Abrams' Abrams Capital Management Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-05-13 00:53:45:000
This article is part of a series that provides an ongoing analysis of the changes made to David Abrams 13F portfolio on a quarterly basis. It is based on Abrams regulatory 13F Form filed on 05/10/2019. Please visit our Tracking David Abrams Abrams Capital Management … read more...
Tracking David Abrams' Abrams Capital Management Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-05-13 00:53:45:000
This article is part of a series that provides an ongoing analysis of the changes made to David Abrams 13F portfolio on a quarterly basis. It is based on Abrams regulatory 13F Form filed on 05/10/2019. Please visit our Tracking David Abrams Abrams Capital Management … read more...
Tracking David Abrams' Abrams Capital Management Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-05-13 00:53:45:000
This article is part of a series that provides an ongoing analysis of the changes made to David Abrams 13F portfolio on a quarterly basis. It is based on Abrams regulatory 13F Form filed on 05/10/2019. Please visit our Tracking David Abrams Abrams Capital Management … read more...
Tracking David Abrams' Abrams Capital Management Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-05-13 00:53:45:000
This article is part of a series that provides an ongoing analysis of the changes made to David Abrams 13F portfolio on a quarterly basis. It is based on Abrams regulatory 13F Form filed on 05/10/2019. Please visit our Tracking David Abrams Abrams Capital Management … read more...
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2019 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-05-09 11:23:22:000
Akebia Therapeutics, Inc. (AKBA) Q1 2019 Results Conference Call May 09, 2019 09:00 AM ET Company Participants Kristen Sheppard - Vice President of Investor Relations John Butler - Chief Executive Officer Jason Amello - Chief Financial Officer Conference Call Participants C… read more...
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2019 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-05-09 11:23:22:000
Akebia Therapeutics, Inc. (AKBA) Q1 2019 Results Conference Call May 09, 2019 09:00 AM ET Company Participants Kristen Sheppard - Vice President of Investor Relations John Butler - Chief Executive Officer Jason Amello - Chief Financial Officer Conference Call Participants C… read more...
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2019 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-05-09 11:23:22:000
Akebia Therapeutics, Inc. (AKBA) Q1 2019 Results Conference Call May 09, 2019 09:00 AM ET Company Participants Kristen Sheppard - Vice President of Investor Relations John Butler - Chief Executive Officer Jason Amello - Chief Financial Officer Conference Call Participants C… read more...
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2019 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-05-09 11:23:22:000
Akebia Therapeutics, Inc. (AKBA) Q1 2019 Results Conference Call May 09, 2019 09:00 AM ET Company Participants Kristen Sheppard - Vice President of Investor Relations John Butler - Chief Executive Officer Jason Amello - Chief Financial Officer Conference Call Participants C… read more...
Akebia misses by $0.22, misses on revenue
via: SeekingAlpha at 2019-05-09 04:04:00:000
Akebia (NASDAQ: AKBA ): Q1 GAAP EPS of -$0.62 misses by $0.22 . More news on: Akebia Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Akebia misses by $0.22, misses on revenue
via: SeekingAlpha at 2019-05-09 04:04:00:000
Akebia (NASDAQ: AKBA ): Q1 GAAP EPS of -$0.62 misses by $0.22 . More news on: Akebia Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Akebia misses by $0.22, misses on revenue
via: SeekingAlpha at 2019-05-09 04:04:00:000
Akebia (NASDAQ: AKBA ): Q1 GAAP EPS of -$0.62 misses by $0.22 . More news on: Akebia Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Akebia misses by $0.22, misses on revenue
via: SeekingAlpha at 2019-05-09 04:04:00:000
Akebia (NASDAQ: AKBA ): Q1 GAAP EPS of -$0.62 misses by $0.22 . More news on: Akebia Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments
via: Business Wire at 2019-05-09 04:00:00:000
Net Product Revenue for Auryxia Increases to $23.1 Million for Q1FY19, Up 12.1% from Q1FY18; Full Enrollment of Phase 3 INNO 2 VATEStudies; and Additions to Executive Leadership Team to Support Commercial and Clinical Operations. Akebia Thera… read more...
Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments
via: Business Wire at 2019-05-09 04:00:00:000
Net Product Revenue for Auryxia Increases to $23.1 Million for Q1FY19, Up 12.1% from Q1FY18; Full Enrollment of Phase 3 INNO 2 VATEStudies; and Additions to Executive Leadership Team to Support Commercial and Clinical Operations. Akebia Thera… read more...
Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments
via: Business Wire at 2019-05-09 04:00:00:000
Net Product Revenue for Auryxia Increases to $23.1 Million for Q1FY19, Up 12.1% from Q1FY18; Full Enrollment of Phase 3 INNO 2 VATEStudies; and Additions to Executive Leadership Team to Support Commercial and Clinical Operations. Akebia Thera… read more...
Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments
via: Business Wire at 2019-05-09 04:00:00:000
Net Product Revenue for Auryxia Increases to $23.1 Million for Q1FY19, Up 12.1% from Q1FY18; Full Enrollment of Phase 3 INNO 2 VATEStudies; and Additions to Executive Leadership Team to Support Commercial and Clinical Operations. Akebia Thera… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-05-02 12:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted nine newly-hired employees options to purchase an aggregate of 95,950 shares of Akebias common stock on A… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-05-02 12:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted nine newly-hired employees options to purchase an aggregate of 95,950 shares of Akebias common stock on A… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-05-02 12:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted nine newly-hired employees options to purchase an aggregate of 95,950 shares of Akebias common stock on A… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-05-02 12:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted nine newly-hired employees options to purchase an aggregate of 95,950 shares of Akebias common stock on A… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-05-02 12:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted nine newly-hired employees options to purchase an aggregate of 95,950 shares of Akebias common stock on A… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-05-02 12:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted nine newly-hired employees options to purchase an aggregate of 95,950 shares of Akebias common stock on A… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-05-02 12:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted nine newly-hired employees options to purchase an aggregate of 95,950 shares of Akebias common stock on A… read more...
UAA, ZNGA among premarket gainers
via: SeekingAlpha at 2019-05-02 05:15:05:000
ARCA biopharma (NASDAQ: ABIO ) +71% . More news on: ARCA biopharma, Inc., Digimarc Corporation, Zynga Inc., Stocks on the move, Read more … read more...
UAA, ZNGA among premarket gainers
via: SeekingAlpha at 2019-05-02 05:15:05:000
ARCA biopharma (NASDAQ: ABIO ) +71% . More news on: ARCA biopharma, Inc., Digimarc Corporation, Zynga Inc., Stocks on the move, Read more … read more...
UAA, ZNGA among premarket gainers
via: SeekingAlpha at 2019-05-02 05:15:05:000
ARCA biopharma (NASDAQ: ABIO ) +71% . More news on: ARCA biopharma, Inc., Digimarc Corporation, Zynga Inc., Stocks on the move, Read more … read more...
UAA, ZNGA among premarket gainers
via: SeekingAlpha at 2019-05-02 05:15:05:000
ARCA biopharma (NASDAQ: ABIO ) +71% . More news on: ARCA biopharma, Inc., Digimarc Corporation, Zynga Inc., Stocks on the move, Read more … read more...
UAA, ZNGA among premarket gainers
via: SeekingAlpha at 2019-05-02 05:15:05:000
ARCA biopharma (NASDAQ: ABIO ) +71% . More news on: ARCA biopharma, Inc., Digimarc Corporation, Zynga Inc., Stocks on the move, Read more … read more...
UAA, ZNGA among premarket gainers
via: SeekingAlpha at 2019-05-02 05:15:05:000
ARCA biopharma (NASDAQ: ABIO ) +71% . More news on: ARCA biopharma, Inc., Digimarc Corporation, Zynga Inc., Stocks on the move, Read more … read more...
UAA, ZNGA among premarket gainers
via: SeekingAlpha at 2019-05-02 05:15:05:000
ARCA biopharma (NASDAQ: ABIO ) +71% . More news on: ARCA biopharma, Inc., Digimarc Corporation, Zynga Inc., Stocks on the move, Read more … read more...
JPMorgan likes Akebia in premarket analyst action
via: SeekingAlpha at 2019-05-02 04:14:04:000
Akebia Therapeutics (NASDAQ: AKBA ) initiated with Overweight rating and $12 (98% upside) price target at JPMorgan. More news on: Akebia Therapeutics, Inc., Athenex, Inc., Premier, Inc., Healthcare stocks news, , Read more … read more...
JPMorgan likes Akebia in premarket analyst action
via: SeekingAlpha at 2019-05-02 04:14:04:000
Akebia Therapeutics (NASDAQ: AKBA ) initiated with Overweight rating and $12 (98% upside) price target at JPMorgan. More news on: Akebia Therapeutics, Inc., Athenex, Inc., Premier, Inc., Healthcare stocks news, , Read more … read more...
JPMorgan likes Akebia in premarket analyst action
via: SeekingAlpha at 2019-05-02 04:14:04:000
Akebia Therapeutics (NASDAQ: AKBA ) initiated with Overweight rating and $12 (98% upside) price target at JPMorgan. More news on: Akebia Therapeutics, Inc., Athenex, Inc., Premier, Inc., Healthcare stocks news, , Read more … read more...
JPMorgan likes Akebia in premarket analyst action
via: SeekingAlpha at 2019-05-02 04:14:04:000
Akebia Therapeutics (NASDAQ: AKBA ) initiated with Overweight rating and $12 (98% upside) price target at JPMorgan. More news on: Akebia Therapeutics, Inc., Athenex, Inc., Premier, Inc., Healthcare stocks news, , Read more … read more...
JPMorgan likes Akebia in premarket analyst action
via: SeekingAlpha at 2019-05-02 04:14:04:000
Akebia Therapeutics (NASDAQ: AKBA ) initiated with Overweight rating and $12 (98% upside) price target at JPMorgan. More news on: Akebia Therapeutics, Inc., Athenex, Inc., Premier, Inc., Healthcare stocks news, , Read more … read more...
JPMorgan likes Akebia in premarket analyst action
via: SeekingAlpha at 2019-05-02 04:14:04:000
Akebia Therapeutics (NASDAQ: AKBA ) initiated with Overweight rating and $12 (98% upside) price target at JPMorgan. More news on: Akebia Therapeutics, Inc., Athenex, Inc., Premier, Inc., Healthcare stocks news, , Read more … read more...
JPMorgan likes Akebia in premarket analyst action
via: SeekingAlpha at 2019-05-02 04:14:04:000
Akebia Therapeutics (NASDAQ: AKBA ) initiated with Overweight rating and $12 (98% upside) price target at JPMorgan. More news on: Akebia Therapeutics, Inc., Athenex, Inc., Premier, Inc., Healthcare stocks news, , Read more … read more...
Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings
via: Business Wire at 2019-05-02 04:00:00:000
Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney dise… read more...
Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings
via: Business Wire at 2019-05-02 04:00:00:000
Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney dise… read more...
Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings
via: Business Wire at 2019-05-02 04:00:00:000
Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney dise… read more...
Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings
via: Business Wire at 2019-05-02 04:00:00:000
Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney dise… read more...
Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings
via: Business Wire at 2019-05-02 04:00:00:000
Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney dise… read more...
Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings
via: Business Wire at 2019-05-02 04:00:00:000
Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney dise… read more...
Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings
via: Business Wire at 2019-05-02 04:00:00:000
Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney dise… read more...
Akebia Therapeutics to Report First Quarter 2019 Financial Results
via: Business Wire at 2019-04-30 04:00:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2019, on Thursday, May 9, 20… read more...
Akebia Therapeutics to Report First Quarter 2019 Financial Results
via: Business Wire at 2019-04-30 04:00:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2019, on Thursday, May 9, 20… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia expands licence agreement
via: SeekingAlpha at 2019-04-09 03:23:24:000
The Vifor Pharma Group ( OTC:GNHAY ) and Akebia Therapeutics (NASDAQ: AKBA ) have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in U.S., subject to FDA approval. More news on: Vifor Pharma AG, Akebia Therapeutics,… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190408005804/en/ T… read more...
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
via: Business Wire at 2019-04-08 21:00:00:000
Expanded license creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license… read more...
Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference
via: Business Wire at 2019-04-05 12:19:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present at the 18 th Annual Needham Hea… read more...
Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference
via: Business Wire at 2019-04-05 12:19:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present at the 18 th Annual Needham Hea… read more...
Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference
via: Business Wire at 2019-04-05 12:19:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present at the 18 th Annual Needham Hea… read more...
Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference
via: Business Wire at 2019-04-05 12:19:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present at the 18 th Annual Needham Hea… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-04-02 12:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 16 newly-hired employees options to purchase an aggregate of 225,000 shares of Akebias common stock on Ma… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-04-02 12:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 16 newly-hired employees options to purchase an aggregate of 225,000 shares of Akebias common stock on Ma… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-04-02 12:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 16 newly-hired employees options to purchase an aggregate of 225,000 shares of Akebias common stock on Ma… read more...
Akebia Therapeutics: Still A Buy Post-Merger
via: SeekingAlpha at 2019-03-25 11:29:14:000
Source: AKBA website On March 18, Akebia Therapeutics (NASDAQ: AKBA ) announced preliminary results for the full-year 2018 . This was its first post-merger earnings announcement. When the merger with Keryx Biopharmaceuticals (formerly NASDAQ: KERX ) was announced on June 28, 2018, the sto… read more...
Akebia Therapeutics: Still A Buy Post-Merger
via: SeekingAlpha at 2019-03-25 11:29:14:000
Source: AKBA website On March 18, Akebia Therapeutics (NASDAQ: AKBA ) announced preliminary results for the full-year 2018 . This was its first post-merger earnings announcement. When the merger with Keryx Biopharmaceuticals (formerly NASDAQ: KERX ) was announced on June 28, 2018, the sto… read more...
Akebia Therapeutics: Still A Buy Post-Merger
via: SeekingAlpha at 2019-03-25 11:29:14:000
Source: AKBA website On March 18, Akebia Therapeutics (NASDAQ: AKBA ) announced preliminary results for the full-year 2018 . This was its first post-merger earnings announcement. When the merger with Keryx Biopharmaceuticals (formerly NASDAQ: KERX ) was announced on June 28, 2018, the sto… read more...
Akebia Therapeutics: Still A Buy Post-Merger
via: SeekingAlpha at 2019-03-25 11:29:14:000
Source: AKBA website On March 18, Akebia Therapeutics (NASDAQ: AKBA ) announced preliminary results for the full-year 2018 . This was its first post-merger earnings announcement. When the merger with Keryx Biopharmaceuticals (formerly NASDAQ: KERX ) was announced on June 28, 2018, the sto… read more...
Akebia Therapeutics: Still A Buy Post-Merger
via: SeekingAlpha at 2019-03-25 11:29:14:000
Source: AKBA website On March 18, Akebia Therapeutics (NASDAQ: AKBA ) announced preliminary results for the full-year 2018 . This was its first post-merger earnings announcement. When the merger with Keryx Biopharmaceuticals (formerly NASDAQ: KERX ) was announced on June 28, 2018, the sto… read more...
Akebia Therapeutics: Still A Buy Post-Merger
via: SeekingAlpha at 2019-03-25 11:29:14:000
Source: AKBA website On March 18, Akebia Therapeutics (NASDAQ: AKBA ) announced preliminary results for the full-year 2018 . This was its first post-merger earnings announcement. When the merger with Keryx Biopharmaceuticals (formerly NASDAQ: KERX ) was announced on June 28, 2018, the sto… read more...
Akebia Therapeutics: Still A Buy Post-Merger
via: SeekingAlpha at 2019-03-25 11:29:14:000
Source: AKBA website On March 18, Akebia Therapeutics (NASDAQ: AKBA ) announced preliminary results for the full-year 2018 . This was its first post-merger earnings announcement. When the merger with Keryx Biopharmaceuticals (formerly NASDAQ: KERX ) was announced on June 28, 2018, the sto… read more...
Akebia Therapeutics: Still A Buy Post-Merger
via: SeekingAlpha at 2019-03-25 11:29:14:000
Source: AKBA website On March 18, Akebia Therapeutics (NASDAQ: AKBA ) announced preliminary results for the full-year 2018 . This was its first post-merger earnings announcement. When the merger with Keryx Biopharmaceuticals (formerly NASDAQ: KERX ) was announced on June 28, 2018, the sto… read more...
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-03-18 19:17:05:000
Akebia Therapeutics, Inc. (AKBA) Q4 2018 Earnings Conference Call March 18, 2019, 16:30 ET Company Participants John Butler - CEO, President & Director Jason Amello - SVP, CFO & Treasurer Michel Dahan - SVP & Chief Business Officer Douglas Jermasek - VP, Marketing &… read more...
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-03-18 19:17:05:000
Akebia Therapeutics, Inc. (AKBA) Q4 2018 Earnings Conference Call March 18, 2019, 16:30 ET Company Participants John Butler - CEO, President & Director Jason Amello - SVP, CFO & Treasurer Michel Dahan - SVP & Chief Business Officer Douglas Jermasek - VP, Marketing &… read more...
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-03-18 19:17:05:000
Akebia Therapeutics, Inc. (AKBA) Q4 2018 Earnings Conference Call March 18, 2019, 16:30 ET Company Participants John Butler - CEO, President & Director Jason Amello - SVP, CFO & Treasurer Michel Dahan - SVP & Chief Business Officer Douglas Jermasek - VP, Marketing &… read more...
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-03-18 19:17:05:000
Akebia Therapeutics, Inc. (AKBA) Q4 2018 Earnings Conference Call March 18, 2019, 16:30 ET Company Participants John Butler - CEO, President & Director Jason Amello - SVP, CFO & Treasurer Michel Dahan - SVP & Chief Business Officer Douglas Jermasek - VP, Marketing &… read more...
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-03-18 19:17:05:000
Akebia Therapeutics, Inc. (AKBA) Q4 2018 Earnings Conference Call March 18, 2019, 16:30 ET Company Participants John Butler - CEO, President & Director Jason Amello - SVP, CFO & Treasurer Michel Dahan - SVP & Chief Business Officer Douglas Jermasek - VP, Marketing &… read more...
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-03-18 19:17:05:000
Akebia Therapeutics, Inc. (AKBA) Q4 2018 Earnings Conference Call March 18, 2019, 16:30 ET Company Participants John Butler - CEO, President & Director Jason Amello - SVP, CFO & Treasurer Michel Dahan - SVP & Chief Business Officer Douglas Jermasek - VP, Marketing &… read more...
Akebia misses on revenue
via: SeekingAlpha at 2019-03-18 12:17:08:000
Akebia (NASDAQ: AKBA ): Q4 Net loss of $88.37M. More news on: Akebia Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights
via: Business Wire at 2019-03-18 12:05:00:000
Substantial revenue growth opportunity for Auryxia following robust 2018 commercial performance First regulatory submission for vadadustat expected in 2019 in Japan, following positive top-line results from pivotal phase 3 studies in Japanese subjects with an… read more...
Week 12 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-03-17 01:53:33:000
The Week 12 - Breakout Stocks for Next Week The two Breakout Stocks to start the week consist of one healthcare and one technology sector stock. Rigel Pharmaceuticals ( RIGL ) - Healthcare Biotechnology Travelzoo ( TZOO ) - Technology/Internet Information Providers Rigel Pha… read more...
NM, SEEL among premarket gainers
via: SeekingAlpha at 2019-03-12 05:14:07:000
Bio-Path Holdings (NASDAQ: BPTH ) +32% . More news on: Bio-Path Holdings, Inc., Stitch Fix, Inc., Akebia Therapeutics, Inc., Stocks on the move, Read more … read more...
NM, SEEL among premarket gainers
via: SeekingAlpha at 2019-03-12 05:14:07:000
Bio-Path Holdings (NASDAQ: BPTH ) +32% . More news on: Bio-Path Holdings, Inc., Stitch Fix, Inc., Akebia Therapeutics, Inc., Stocks on the move, Read more … read more...
NM, SEEL among premarket gainers
via: SeekingAlpha at 2019-03-12 05:14:07:000
Bio-Path Holdings (NASDAQ: BPTH ) +32% . More news on: Bio-Path Holdings, Inc., Stitch Fix, Inc., Akebia Therapeutics, Inc., Stocks on the move, Read more … read more...
NM, SEEL among premarket gainers
via: SeekingAlpha at 2019-03-12 05:14:07:000
Bio-Path Holdings (NASDAQ: BPTH ) +32% . More news on: Bio-Path Holdings, Inc., Stitch Fix, Inc., Akebia Therapeutics, Inc., Stocks on the move, Read more … read more...
NM, SEEL among premarket gainers
via: SeekingAlpha at 2019-03-12 05:14:07:000
Bio-Path Holdings (NASDAQ: BPTH ) +32% . More news on: Bio-Path Holdings, Inc., Stitch Fix, Inc., Akebia Therapeutics, Inc., Stocks on the move, Read more … read more...
Akebia up 38% premarket on positive vadadustat data
via: SeekingAlpha at 2019-03-12 03:26:25:000
Akebia Therapeutics (NASDAQ: AKBA ) is up 38% premarket on light volume in response to positive topline results from two Phase 3 clinical trials evaluating vadadustat in Japanese patients with anemia due to chronic kidney disease (CKD). More news on: Akebia Therapeutics, Inc…. read more...
Akebia up 38% premarket on positive vadadustat data
via: SeekingAlpha at 2019-03-12 03:26:25:000
Akebia Therapeutics (NASDAQ: AKBA ) is up 38% premarket on light volume in response to positive topline results from two Phase 3 clinical trials evaluating vadadustat in Japanese patients with anemia due to chronic kidney disease (CKD). More news on: Akebia Therapeutics, Inc…. read more...
Akebia up 38% premarket on positive vadadustat data
via: SeekingAlpha at 2019-03-12 03:26:25:000
Akebia Therapeutics (NASDAQ: AKBA ) is up 38% premarket on light volume in response to positive topline results from two Phase 3 clinical trials evaluating vadadustat in Japanese patients with anemia due to chronic kidney disease (CKD). More news on: Akebia Therapeutics, Inc…. read more...
Akebia up 38% premarket on positive vadadustat data
via: SeekingAlpha at 2019-03-12 03:26:25:000
Akebia Therapeutics (NASDAQ: AKBA ) is up 38% premarket on light volume in response to positive topline results from two Phase 3 clinical trials evaluating vadadustat in Japanese patients with anemia due to chronic kidney disease (CKD). More news on: Akebia Therapeutics, Inc…. read more...
Akebia up 38% premarket on positive vadadustat data
via: SeekingAlpha at 2019-03-12 03:26:25:000
Akebia Therapeutics (NASDAQ: AKBA ) is up 38% premarket on light volume in response to positive topline results from two Phase 3 clinical trials evaluating vadadustat in Japanese patients with anemia due to chronic kidney disease (CKD). More news on: Akebia Therapeutics, Inc…. read more...
Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease
via: Business Wire at 2019-03-12 00:00:00:000
Each Study Met Its Primary Endpoint Regulatory Submission in Japan Expected in 2019 Akebia Therapeutics , Inc. (Nasdaq:AKBA) today announced positive top-line results from two phase 3 active-controlled pivotal studies evaluating vadadustat, an… read more...
Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease
via: Business Wire at 2019-03-12 00:00:00:000
Each Study Met Its Primary Endpoint Regulatory Submission in Japan Expected in 2019 Akebia Therapeutics , Inc. (Nasdaq:AKBA) today announced positive top-line results from two phase 3 active-controlled pivotal studies evaluating vadadustat, an… read more...
Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease
via: Business Wire at 2019-03-12 00:00:00:000
Each Study Met Its Primary Endpoint Regulatory Submission in Japan Expected in 2019 Akebia Therapeutics , Inc. (Nasdaq:AKBA) today announced positive top-line results from two phase 3 active-controlled pivotal studies evaluating vadadustat, an… read more...
Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease
via: Business Wire at 2019-03-12 00:00:00:000
Each Study Met Its Primary Endpoint Regulatory Submission in Japan Expected in 2019 Akebia Therapeutics , Inc. (Nasdaq:AKBA) today announced positive top-line results from two phase 3 active-controlled pivotal studies evaluating vadadustat, an… read more...
Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease
via: Business Wire at 2019-03-12 00:00:00:000
Each Study Met Its Primary Endpoint Regulatory Submission in Japan Expected in 2019 Akebia Therapeutics , Inc. (Nasdaq:AKBA) today announced positive top-line results from two phase 3 active-controlled pivotal studies evaluating vadadustat, an… read more...
Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast
via: Business Wire at 2019-03-06 02:00:00:000
Akebia Therapeutics , Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced it will host a fourth quarter and full-year 2018 investor update conference call and webcast at 4:30 p.m. … read more...
Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast
via: Business Wire at 2019-03-06 02:00:00:000
Akebia Therapeutics , Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced it will host a fourth quarter and full-year 2018 investor update conference call and webcast at 4:30 p.m. … read more...
Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast
via: Business Wire at 2019-03-06 02:00:00:000
Akebia Therapeutics , Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced it will host a fourth quarter and full-year 2018 investor update conference call and webcast at 4:30 p.m. … read more...
Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast
via: Business Wire at 2019-03-06 02:00:00:000
Akebia Therapeutics , Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced it will host a fourth quarter and full-year 2018 investor update conference call and webcast at 4:30 p.m. … read more...
Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast
via: Business Wire at 2019-03-06 02:00:00:000
Akebia Therapeutics , Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced it will host a fourth quarter and full-year 2018 investor update conference call and webcast at 4:30 p.m. … read more...
Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast
via: Business Wire at 2019-03-06 02:00:00:000
Akebia Therapeutics , Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced it will host a fourth quarter and full-year 2018 investor update conference call and webcast at 4:30 p.m. … read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-03-04 11:05:00:000
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 11 newly-hired employees options to purchase an aggregate of 32,800 shares of Akebias common stock on Feb… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-03-04 11:05:00:000
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 11 newly-hired employees options to purchase an aggregate of 32,800 shares of Akebias common stock on Feb… read more...
Week 10 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-03-03 10:07:41:000
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on winning breakout selections over more than 5 years including 94 weeks of public weekly selections as part of this ongoing live forward-testing. Breakout Stock Portfolio 2019 results YTD All time total… read more...
Tracking David Abrams' Abrams Capital Management Portfolio - Q4 2018 Update
via: SeekingAlpha at 2019-02-28 21:05:00:000
This article is part of a series that provides an ongoing analysis of the changes made to David Abrams 13F portfolio on a quarterly basis. It is based on Abrams regulatory 13F Form filed on 02/14/2019. Please visit our Tracking David Abrams Abrams Capital Management … read more...
Tracking David Abrams' Abrams Capital Management Portfolio - Q4 2018 Update
via: SeekingAlpha at 2019-02-28 21:05:00:000
This article is part of a series that provides an ongoing analysis of the changes made to David Abrams 13F portfolio on a quarterly basis. It is based on Abrams regulatory 13F Form filed on 02/14/2019. Please visit our Tracking David Abrams Abrams Capital Management … read more...
Week 9 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-02-23 05:57:34:000
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +61.60% Cumulative Gain by Friday of the Week: -3.60% This week 3 out of 4 breakout stocks for members reached double digits during a short trading week. Selling of the breakout stocks prior to the end of t… read more...
Week 9 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-02-23 05:57:34:000
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +61.60% Cumulative Gain by Friday of the Week: -3.60% This week 3 out of 4 breakout stocks for members reached double digits during a short trading week. Selling of the breakout stocks prior to the end of t… read more...
Week 9 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-02-23 05:57:34:000
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +61.60% Cumulative Gain by Friday of the Week: -3.60% This week 3 out of 4 breakout stocks for members reached double digits during a short trading week. Selling of the breakout stocks prior to the end of t… read more...
Week 9 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-02-23 05:57:34:000
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +61.60% Cumulative Gain by Friday of the Week: -3.60% This week 3 out of 4 breakout stocks for members reached double digits during a short trading week. Selling of the breakout stocks prior to the end of t… read more...
Week 9 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-02-23 05:57:34:000
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +61.60% Cumulative Gain by Friday of the Week: -3.60% This week 3 out of 4 breakout stocks for members reached double digits during a short trading week. Selling of the breakout stocks prior to the end of t… read more...
Week 9 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-02-23 05:57:34:000
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +61.60% Cumulative Gain by Friday of the Week: -3.60% This week 3 out of 4 breakout stocks for members reached double digits during a short trading week. Selling of the breakout stocks prior to the end of t… read more...
Tracking Seth Klarman's Baupost Group Holdings - Q4 2018 Update
via: SeekingAlpha at 2019-02-14 08:33:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 02/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for … read more...
Tracking Seth Klarman's Baupost Group Holdings - Q4 2018 Update
via: SeekingAlpha at 2019-02-14 08:33:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 02/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for … read more...
Tracking Seth Klarman's Baupost Group Holdings - Q4 2018 Update
via: SeekingAlpha at 2019-02-14 08:33:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 02/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for … read more...
Tracking Seth Klarman's Baupost Group Holdings - Q4 2018 Update
via: SeekingAlpha at 2019-02-14 08:33:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 02/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for … read more...
Tracking Seth Klarman's Baupost Group Holdings - Q4 2018 Update
via: SeekingAlpha at 2019-02-14 08:33:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 02/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for … read more...
Tracking Seth Klarman's Baupost Group Holdings - Q4 2018 Update
via: SeekingAlpha at 2019-02-14 08:33:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 02/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for … read more...
Tracking Seth Klarman's Baupost Group Holdings - Q4 2018 Update
via: SeekingAlpha at 2019-02-14 08:33:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 02/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for … read more...
Tracking Seth Klarman's Baupost Group Holdings - Q4 2018 Update
via: SeekingAlpha at 2019-02-14 08:33:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 02/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for … read more...
Tracking Seth Klarman's Baupost Group Holdings - Q4 2018 Update
via: SeekingAlpha at 2019-02-14 08:33:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 02/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for … read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-02-04 16:05:00:000
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 11 newly-hired employees options to purchase an aggregate of 41,900 shares of Akebias common stock on Jan… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-02-04 16:05:00:000
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 11 newly-hired employees options to purchase an aggregate of 41,900 shares of Akebias common stock on Jan… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-02-04 16:05:00:000
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 11 newly-hired employees options to purchase an aggregate of 41,900 shares of Akebias common stock on Jan… read more...
FDA OK's three-year NCE exclusivity for Akebia's Auryxia, says no to five years
via: SeekingAlpha at 2019-01-31 16:14:59:000
The FDA has denied a request by Keryx Biopharmaceuticals, now doing business as Akebia Therapeutics (NASDAQ: AKBA ) subsequent to the completion of their merger last month, seeking five-year new chemical entity exclusivity for Auryxia (ferric citrate), first approved by in the U.S. in Novemb… read more...
FDA OK's three-year NCE exclusivity for Akebia's Auryxia, says no to five years
via: SeekingAlpha at 2019-01-31 16:14:59:000
The FDA has denied a request by Keryx Biopharmaceuticals, now doing business as Akebia Therapeutics (NASDAQ: AKBA ) subsequent to the completion of their merger last month, seeking five-year new chemical entity exclusivity for Auryxia (ferric citrate), first approved by in the U.S. in Novemb… read more...
FDA OK's three-year NCE exclusivity for Akebia's Auryxia, says no to five years
via: SeekingAlpha at 2019-01-31 16:14:59:000
The FDA has denied a request by Keryx Biopharmaceuticals, now doing business as Akebia Therapeutics (NASDAQ: AKBA ) subsequent to the completion of their merger last month, seeking five-year new chemical entity exclusivity for Auryxia (ferric citrate), first approved by in the U.S. in Novemb… read more...
Akebia: Is This A Potential Winner?
via: SeekingAlpha at 2019-01-11 16:13:00:000
With every new wave of optimism or pessimism, we are ready to abandon history and time-tested principles, but we cling tenaciously and unquestioningly to our prejudices. - Benjamin Graham Back on Dec. 13, 2018, Keryx Pharmaceuticals and Akebia Therapeutics (NASDAQ: AKBA ) announced the c… read more...
Akebia: Is This A Potential Winner?
via: SeekingAlpha at 2019-01-11 16:13:00:000
With every new wave of optimism or pessimism, we are ready to abandon history and time-tested principles, but we cling tenaciously and unquestioningly to our prejudices. - Benjamin Graham Back on Dec. 13, 2018, Keryx Pharmaceuticals and Akebia Therapeutics (NASDAQ: AKBA ) announced the c… read more...
Akebia: Is This A Potential Winner?
via: SeekingAlpha at 2019-01-11 16:13:00:000
With every new wave of optimism or pessimism, we are ready to abandon history and time-tested principles, but we cling tenaciously and unquestioningly to our prejudices. - Benjamin Graham Back on Dec. 13, 2018, Keryx Pharmaceuticals and Akebia Therapeutics (NASDAQ: AKBA ) announced the c… read more...
Akebia: Is This A Potential Winner?
via: SeekingAlpha at 2019-01-11 16:13:00:000
With every new wave of optimism or pessimism, we are ready to abandon history and time-tested principles, but we cling tenaciously and unquestioningly to our prejudices. - Benjamin Graham Back on Dec. 13, 2018, Keryx Pharmaceuticals and Akebia Therapeutics (NASDAQ: AKBA ) announced the c… read more...
Akebia: Is This A Potential Winner?
via: SeekingAlpha at 2019-01-11 16:13:00:000
With every new wave of optimism or pessimism, we are ready to abandon history and time-tested principles, but we cling tenaciously and unquestioningly to our prejudices. - Benjamin Graham Back on Dec. 13, 2018, Keryx Pharmaceuticals and Akebia Therapeutics (NASDAQ: AKBA ) announced the c… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-01-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted six newly-hired employees options to purchase an aggregate of 45,150 shares of Akebias common stock on De… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-01-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted six newly-hired employees options to purchase an aggregate of 45,150 shares of Akebias common stock on De… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2019-01-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted six newly-hired employees options to purchase an aggregate of 45,150 shares of Akebias common stock on De… read more...
Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
via: Business Wire at 2019-01-02 07:00:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will present at the 37 th Annual J.P. Mo… read more...
Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
via: Business Wire at 2019-01-02 07:00:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will present at the 37 th Annual J.P. Mo… read more...
Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
via: Business Wire at 2019-01-02 07:00:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will present at the 37 th Annual J.P. Mo… read more...
Merger Arbitrage Mondays - December 17, 2018
via: SeekingAlpha at 2018-12-17 10:51:03:000
Merger activity increased last week with five new deals announced and five pending deals closing. Deal Statistics: New Deals: The acquisition of Nutrisystem (NTRI) by Tivity Health (TVTY) for $1.4 billion in a cash plus stock deal. Under the terms of the merger agreement, each o… read more...
Merger Arbitrage Mondays - December 17, 2018
via: SeekingAlpha at 2018-12-17 10:51:03:000
Merger activity increased last week with five new deals announced and five pending deals closing. Deal Statistics: New Deals: The acquisition of Nutrisystem (NTRI) by Tivity Health (TVTY) for $1.4 billion in a cash plus stock deal. Under the terms of the merger agreement, each o… read more...
Merger Arbitrage Mondays - December 17, 2018
via: SeekingAlpha at 2018-12-17 10:51:03:000
Merger activity increased last week with five new deals announced and five pending deals closing. Deal Statistics: New Deals: The acquisition of Nutrisystem (NTRI) by Tivity Health (TVTY) for $1.4 billion in a cash plus stock deal. Under the terms of the merger agreement, each o… read more...
Keryx's Long-Awaited Merger With Akebia Complete
via: SeekingAlpha at 2018-12-17 10:38:08:000
Two Heads Are Better Than One Akebia Therapeutics ( AKBA ) recently announced that their shareholders voted to approve the share issuance proposal required to complete the merger with Keryx Biopharmaceuticals ( KERX ). The merger, completed on December 12th, 2018, offers up to $250M in p… read more...
Keryx's Long-Awaited Merger With Akebia Complete
via: SeekingAlpha at 2018-12-17 10:38:08:000
Two Heads Are Better Than One Akebia Therapeutics ( AKBA ) recently announced that their shareholders voted to approve the share issuance proposal required to complete the merger with Keryx Biopharmaceuticals ( KERX ). The merger, completed on December 12th, 2018, offers up to $250M in p… read more...
Keryx's Long-Awaited Merger With Akebia Complete
via: SeekingAlpha at 2018-12-17 10:38:08:000
Two Heads Are Better Than One Akebia Therapeutics ( AKBA ) recently announced that their shareholders voted to approve the share issuance proposal required to complete the merger with Keryx Biopharmaceuticals ( KERX ). The merger, completed on December 12th, 2018, offers up to $250M in p… read more...
Akebia Therapeutics and Keryx Biopharmaceuticals complete merger
via: SeekingAlpha at 2018-12-13 07:46:19:000
Akebia Therapeutics (NASDAQ: AKBA ) and Keryx Biopharmaceuticals (NASDAQ: KERX ) successfully completed their previously announced merger. More news on: Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Akebia Therapeutics and Keryx Biopharmaceuticals complete merger
via: SeekingAlpha at 2018-12-13 07:46:19:000
Akebia Therapeutics (NASDAQ: AKBA ) and Keryx Biopharmaceuticals (NASDAQ: KERX ) successfully completed their previously announced merger. More news on: Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Akebia Therapeutics and Keryx Biopharmaceuticals complete merger
via: SeekingAlpha at 2018-12-13 07:46:19:000
Akebia Therapeutics (NASDAQ: AKBA ) and Keryx Biopharmaceuticals (NASDAQ: KERX ) successfully completed their previously announced merger. More news on: Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company
via: Business Wire at 2018-12-13 07:00:00:000
Akebia Therapeutics, Inc. (Nasdaq:AKBA) and Keryx Biopharmaceuticals, Inc. today announced the successful completion of their previously announced merger. "We are very pleased to announce the completion of our merger with Keryx to create a fully integrated renal company that has the pote… read more...
Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company
via: Business Wire at 2018-12-13 07:00:00:000
Akebia Therapeutics, Inc. (Nasdaq:AKBA) and Keryx Biopharmaceuticals, Inc. today announced the successful completion of their previously announced merger. "We are very pleased to announce the completion of our merger with Keryx to create a fully integrated renal company that has the pote… read more...
Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company
via: Business Wire at 2018-12-13 07:00:00:000
Akebia Therapeutics, Inc. (Nasdaq:AKBA) and Keryx Biopharmaceuticals, Inc. today announced the successful completion of their previously announced merger. "We are very pleased to announce the completion of our merger with Keryx to create a fully integrated renal company that has the pote… read more...
Midday movers and shakers
via: SeekingAlpha at 2018-12-12 12:51:18:000
Gainers: Sparton (NYSE: SPA ) +39% .Uxin Limited (NASDAQ: UXIN ) +31% . Teligent (NASDAQ: TLGT ) +32% . Astrotech (NASDAQ: ASTC ) +28% . LexinFintech Holdings (NASDAQ: LX ) +22% . Live Oak Bancshares (NASDAQ: LOB ) +21% . Galmed Pharmaceuticals (NASDAQ: GLMD ) +18% . Pux… read more...
Stocks To Watch: Tencent Music, Starbucks And Under Armour In Focus
via: SeekingAlpha at 2018-12-08 09:31:22:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are prepping for another week of volatility as concerns over the China tr… read more...
Stocks To Watch: Tencent Music, Starbucks And Under Armour In Focus
via: SeekingAlpha at 2018-12-08 09:31:22:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are prepping for another week of volatility as concerns over the China tr… read more...
Stocks To Watch: Tencent Music, Starbucks And Under Armour In Focus
via: SeekingAlpha at 2018-12-08 09:31:22:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are prepping for another week of volatility as concerns over the China tr… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-12-03 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted five newly-hired employees options to purchase an aggregate of 49,650 shares of Ake… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-12-03 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted five newly-hired employees options to purchase an aggregate of 49,650 shares of Ake… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-12-03 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted five newly-hired employees options to purchase an aggregate of 49,650 shares of Ake… read more...
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote "FOR" Proposed Merger with Keryx
via: Business Wire at 2018-11-30 08:55:00:000
Akebia Urges Shareholders to Vote FOR the Merger-Related Shareholder Proposals Today Akebia Therapeutics, Inc. (Nasdaq:AKBA) (Akebia or the Company) today announced that leading independent proxy advisory firm, Glass Lewis & Co. (&#x… read more...
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote "FOR" Proposed Merger with Keryx
via: Business Wire at 2018-11-30 08:55:00:000
Akebia Urges Shareholders to Vote FOR the Merger-Related Shareholder Proposals Today Akebia Therapeutics, Inc. (Nasdaq:AKBA) (Akebia or the Company) today announced that leading independent proxy advisory firm, Glass Lewis & Co. (&#x… read more...
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote "FOR" Proposed Merger with Keryx
via: Business Wire at 2018-11-30 08:55:00:000
Akebia Urges Shareholders to Vote FOR the Merger-Related Shareholder Proposals Today Akebia Therapeutics, Inc. (Nasdaq:AKBA) (Akebia or the Company) today announced that leading independent proxy advisory firm, Glass Lewis & Co. (&#x… read more...
Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote "FOR" Proposed Merger with Keryx
via: Business Wire at 2018-11-29 07:00:00:000
Akebia Urges Shareholders to Vote FOR the Merger-Related Shareholder Proposals Today Akebia Therapeutics, Inc. (Nasdaq:AKBA) (Akebia or the Company) today announced that leading independent proxy advisory firm, Institutional Shareholder … read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2018-11-20 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will participate in the following investor conferences: The … read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2018-11-20 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will participate in the following investor conferences: The … read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2018-11-20 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will participate in the following investor conferences: The … read more...
Akebia Therapeutics Is An Attractive Investment In 2018
via: SeekingAlpha at 2018-11-16 17:42:35:000
Headquartered in Cambridge, Massachusetts, Akebia Therapeutics ( AKBA ) has taken on the fast track route to transform from being a development-stage company to a leading fully integrated renal company with an anticipated pro-forma market capitalization of over $1.0 billion . The merger wit… read more...
Akebia Therapeutics Is An Attractive Investment In 2018
via: SeekingAlpha at 2018-11-16 17:42:35:000
Headquartered in Cambridge, Massachusetts, Akebia Therapeutics ( AKBA ) has taken on the fast track route to transform from being a development-stage company to a leading fully integrated renal company with an anticipated pro-forma market capitalization of over $1.0 billion . The merger wit… read more...
Akebia Therapeutics Is An Attractive Investment In 2018
via: SeekingAlpha at 2018-11-16 17:42:35:000
Headquartered in Cambridge, Massachusetts, Akebia Therapeutics ( AKBA ) has taken on the fast track route to transform from being a development-stage company to a leading fully integrated renal company with an anticipated pro-forma market capitalization of over $1.0 billion . The merger wit… read more...
Akebia Therapeutics Is An Attractive Investment In 2018
via: SeekingAlpha at 2018-11-16 17:42:35:000
Headquartered in Cambridge, Massachusetts, Akebia Therapeutics ( AKBA ) has taken on the fast track route to transform from being a development-stage company to a leading fully integrated renal company with an anticipated pro-forma market capitalization of over $1.0 billion . The merger wit… read more...
Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company
via: Business Wire at 2018-11-15 17:15:00:000
Adrian Adams To Serve as Independent Chairperson of the Board After Merger Akebia Therapeutics , Inc. (Nasdaq: AKBA), and Keryx Biopharmaceuticals , Inc. (Nasdaq: KERX) today announced that Adrian Adams will serve as the Chairperson of the Akebia Board of Directors, effective upon c… read more...
Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company
via: Business Wire at 2018-11-15 17:15:00:000
Adrian Adams To Serve as Independent Chairperson of the Board After Merger Akebia Therapeutics , Inc. (Nasdaq: AKBA), and Keryx Biopharmaceuticals , Inc. (Nasdaq: KERX) today announced that Adrian Adams will serve as the Chairperson of the Akebia Board of Directors, effective upon c… read more...
Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company
via: Business Wire at 2018-11-15 17:15:00:000
Adrian Adams To Serve as Independent Chairperson of the Board After Merger Akebia Therapeutics , Inc. (Nasdaq: AKBA), and Keryx Biopharmaceuticals , Inc. (Nasdaq: KERX) today announced that Adrian Adams will serve as the Chairperson of the Akebia Board of Directors, effective upon c… read more...
Tracking Seth Klarman's Baupost Group Holdings - Q3 2018 Update
via: SeekingAlpha at 2018-11-14 17:26:08:000
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 11/13/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...
Tracking Seth Klarman's Baupost Group Holdings - Q3 2018 Update
via: SeekingAlpha at 2018-11-14 17:26:08:000
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 11/13/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...
Akebia Therapeutics Sends Letter to Shareholders
via: Business Wire at 2018-11-13 16:05:00:000
Recommends Shareholders Vote FOR the Proposals Relating to the Merger Akebia Therapeutics, Inc. (Nasdaq: AKBA) mailed a letter to Akebia shareholders in connection with the special meeting of Akebia shareholders (the Special Meeting) that has been calle… read more...
Akebia Therapeutics Sends Letter to Shareholders
via: Business Wire at 2018-11-13 16:05:00:000
Recommends Shareholders Vote FOR the Proposals Relating to the Merger Akebia Therapeutics, Inc. (Nasdaq: AKBA) mailed a letter to Akebia shareholders in connection with the special meeting of Akebia shareholders (the Special Meeting) that has been calle… read more...
Tracking David Abrams' Abrams Capital Management Portfolio - Q3 2018 Update
via: SeekingAlpha at 2018-11-12 05:06:01:000
This article is part of a series that provides an ongoing analysis of the changes made to David Abrams' 13F portfolio on a quarterly basis. It is based on Abrams' regulatory 13F Form filed on 11/09/2018. Please visit our Tracking David Abrams' Abrams Capital Management article for an idea … read more...
Akebia beats by $0.17, beats on revenue
via: SeekingAlpha at 2018-11-08 17:02:33:000
Akebia (NASDAQ: AKBA ): Q3 GAAP EPS of -$0.46 beats by $0.17 . More news on: Akebia Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Akebia beats by $0.17, beats on revenue
via: SeekingAlpha at 2018-11-08 17:02:33:000
Akebia (NASDAQ: AKBA ): Q3 GAAP EPS of -$0.46 beats by $0.17 . More news on: Akebia Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Akebia beats by $0.17, beats on revenue
via: SeekingAlpha at 2018-11-08 17:02:33:000
Akebia (NASDAQ: AKBA ): Q3 GAAP EPS of -$0.46 beats by $0.17 . More news on: Akebia Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Akebia Therapeutics Announces Third Quarter 2018 Financial Results
via: Business Wire at 2018-11-08 16:30:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2018. … read more...
Akebia Therapeutics Announces Third Quarter 2018 Financial Results
via: Business Wire at 2018-11-08 16:30:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2018. … read more...
Akebia Therapeutics Announces Third Quarter 2018 Financial Results
via: Business Wire at 2018-11-08 16:30:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2018. … read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-11-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted four newly-hired employees options to purchase an aggregate of 25,400 shares of Ak… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-11-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted four newly-hired employees options to purchase an aggregate of 25,400 shares of Ak… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-11-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted four newly-hired employees options to purchase an aggregate of 25,400 shares of Ak… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-11-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted four newly-hired employees options to purchase an aggregate of 25,400 shares of Ak… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-11-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted four newly-hired employees options to purchase an aggregate of 25,400 shares of Ak… read more...
Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals
via: Business Wire at 2018-10-30 17:35:00:000
Mails Letter to Shareholders Highlighting Accelerated Growth Opportunity Details Enhanced Market Position, Capital Resources and Cost Savings to Deliver Enhanced and Sustained Shareholder Value Urges Shareholders to Vote FOR the Proposals Relating to the Merger … read more...
Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals
via: Business Wire at 2018-10-30 17:35:00:000
Mails Letter to Shareholders Highlighting Accelerated Growth Opportunity Details Enhanced Market Position, Capital Resources and Cost Savings to Deliver Enhanced and Sustained Shareholder Value Urges Shareholders to Vote FOR the Proposals Relating to the Merger … read more...
Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals
via: Business Wire at 2018-10-30 17:35:00:000
Mails Letter to Shareholders Highlighting Accelerated Growth Opportunity Details Enhanced Market Position, Capital Resources and Cost Savings to Deliver Enhanced and Sustained Shareholder Value Urges Shareholders to Vote FOR the Proposals Relating to the Merger … read more...
Akebia Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2018 Annual Meeting
via: Business Wire at 2018-10-09 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced two posters to be presented at the upcoming American Society of Nephrology… read more...
Akebia Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2018 Annual Meeting
via: Business Wire at 2018-10-09 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced two posters to be presented at the upcoming American Society of Nephrology… read more...
Akebia Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2018 Annual Meeting
via: Business Wire at 2018-10-09 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced two posters to be presented at the upcoming American Society of Nephrology… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-10-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted six newly-hired employees options to purchase an aggregate of 32,750 shares of Ake… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-10-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted six newly-hired employees options to purchase an aggregate of 32,750 shares of Ake… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-10-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted six newly-hired employees options to purchase an aggregate of 32,750 shares of Ake… read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2018-09-25 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will participate in the following investor conferences: The … read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2018-09-25 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will participate in the following investor conferences: The … read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2018-09-25 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will participate in the following investor conferences: The … read more...
Akebia Therapeutics (AKBA) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow
via: SeekingAlpha at 2018-09-07 13:32:26:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia Therapeutics (AKBA) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow
via: SeekingAlpha at 2018-09-07 13:32:26:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia Therapeutics (AKBA) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow
via: SeekingAlpha at 2018-09-07 13:32:26:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia Therapeutics (AKBA) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow
via: SeekingAlpha at 2018-09-07 13:32:26:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia Therapeutics (AKBA) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow
via: SeekingAlpha at 2018-09-07 13:32:26:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-09-04 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted a newly-hired employee options to purchase an aggregate of 1,250 shares of Akebia&… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-09-04 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted a newly-hired employee options to purchase an aggregate of 1,250 shares of Akebia&… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-09-04 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted a newly-hired employee options to purchase an aggregate of 1,250 shares of Akebia&… read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2018-08-30 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participa… read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2018-08-30 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participa… read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2018-08-30 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participa… read more...
Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors
via: Business Wire at 2018-08-28 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the appointment of Cynthia Smith to its Board of Directors. Cy… read more...
Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors
via: Business Wire at 2018-08-28 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the appointment of Cynthia Smith to its Board of Directors. Cy… read more...
Tracking Seth Klarman's Baupost Group Holdings - Q2 2018 Update
via: SeekingAlpha at 2018-08-14 05:08:29:000
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 08/13/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...
Tracking Seth Klarman's Baupost Group Holdings - Q2 2018 Update
via: SeekingAlpha at 2018-08-14 05:08:29:000
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 08/13/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...
Tracking Seth Klarman's Baupost Group Holdings - Q2 2018 Update
via: SeekingAlpha at 2018-08-14 05:08:29:000
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 08/13/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings … read more...
Akebia Therapeutics Inc (AKBA) CEO John Butler on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-08 23:08:15:000
Akebia Therapeutics Inc (AKBA) Q2 2018 Earnings Conference Call August 08, 2018 04:30 PM ET Executives John Garabo - Director of Corporate Communications John Butler - President and Chief Executive Officer Jason Amello - Senior Vice President and Chief Financial Officer Dr. Rit… read more...
Akebia Therapeutics Inc (AKBA) CEO John Butler on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-08 23:08:15:000
Akebia Therapeutics Inc (AKBA) Q2 2018 Earnings Conference Call August 08, 2018 04:30 PM ET Executives John Garabo - Director of Corporate Communications John Butler - President and Chief Executive Officer Jason Amello - Senior Vice President and Chief Financial Officer Dr. Rit… read more...
Akebia Therapeutics Inc (AKBA) CEO John Butler on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-08 23:08:15:000
Akebia Therapeutics Inc (AKBA) Q2 2018 Earnings Conference Call August 08, 2018 04:30 PM ET Executives John Garabo - Director of Corporate Communications John Butler - President and Chief Executive Officer Jason Amello - Senior Vice President and Chief Financial Officer Dr. Rit… read more...
After Hours Gainers / Losers (08/08/2018)
via: SeekingAlpha at 2018-08-08 17:40:55:000
Top Gainers: YELP +11.3% . SAIL +10.3%. CVNA +9.8% . MFIN +9.4% . ROKU +9.2% . More news on: Yelp, SailPoint Technologies, Carvana Co., Stocks on the move, , Read more … read more...
Akebia misses by $0.09, misses on revenue
via: SeekingAlpha at 2018-08-08 16:57:51:000
Akebia (NASDAQ: AKBA ): Q2 EPS of -$0.60 misses by $0.09 . More news on: Akebia Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Akebia Therapeutics Announces Second Quarter 2018 Financial Results
via: Business Wire at 2018-08-08 16:05:00:000
--Company to Host Conference Call Today at 4:30 p.m. Eastern Time-- Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-08-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted eight newly-hired employees options to purchase an aggregate of 37,400 shares of A… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-08-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted eight newly-hired employees options to purchase an aggregate of 37,400 shares of A… read more...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
via: Business Wire at 2018-08-02 16:05:00:000
Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted eight newly-hired employees options to purchase an aggregate of 37,400 shares of A… read more...
Akebia Therapeutics to Host Second Quarter 2018 Investor Update Call and Webcast
via: Business Wire at 2018-08-01 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced it will host a second quarter 2018 investor update conference call and webc… read more...
Wolf Popper LLP Investigates the Proposed Acquisition of Keryx Biopharmaceuticals, Inc. by Akebia Therapeutics, Inc.
via: PR Newswire at 2018-07-23 14:43:00:000
NEW YORK , July 23, 2018 /PRNewswire/ --Wolf Popper LLP is investigating claims on behalf of investors in Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), concerning the proposed acquisition of Keryx by Akebia Therapeutics, Inc. (NASDAQ: AKBA). Under the terms of the agreement, … read more...
Wolf Popper LLP Investigates the Proposed Acquisition of Keryx Biopharmaceuticals, Inc. by Akebia Therapeutics, Inc.
via: PR Newswire at 2018-07-23 14:43:00:000
NEW YORK , July 23, 2018 /PRNewswire/ --Wolf Popper LLP is investigating claims on behalf of investors in Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), concerning the proposed acquisition of Keryx by Akebia Therapeutics, Inc. (NASDAQ: AKBA). Under the terms of the agreement, … read more...
Wolf Popper LLP Investigates the Proposed Acquisition of Keryx Biopharmaceuticals, Inc. by Akebia Therapeutics, Inc.
via: PR Newswire at 2018-07-23 14:43:00:000
NEW YORK , July 23, 2018 /PRNewswire/ --Wolf Popper LLP is investigating claims on behalf of investors in Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), concerning the proposed acquisition of Keryx by Akebia Therapeutics, Inc. (NASDAQ: AKBA). Under the terms of the agreement, … read more...
Playing The Expectations Game In Biotech
via: SeekingAlpha at 2018-07-17 21:11:17:000
Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th… read more...
Playing The Expectations Game In Biotech
via: SeekingAlpha at 2018-07-17 21:11:17:000
Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th… read more...
Playing The Expectations Game In Biotech
via: SeekingAlpha at 2018-07-17 21:11:17:000
Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th… read more...
Keryx Biopharmaceuticals And Akebia Therapeutics: Was The Reaction To The Merger Announcement Justified?
via: SeekingAlpha at 2018-07-06 13:09:56:000
By Eric Egana and Elle Investments On Thursday, June 28, Keryx Biopharmaceuticals (NASDAQ:KERX) and Akebia Therapeutics (NASDAQ:AKBA) announced they would combine in an all-stock merger. The Baupost Group (the largest KERX shareholder, owning approximately 21.4% of the outstanding KERX c… read more...
Keryx Biopharmaceuticals And Akebia Therapeutics: Was The Reaction To The Merger Announcement Justified?
via: SeekingAlpha at 2018-07-06 13:09:56:000
By Eric Egana and Elle Investments On Thursday, June 28, Keryx Biopharmaceuticals (NASDAQ:KERX) and Akebia Therapeutics (NASDAQ:AKBA) announced they would combine in an all-stock merger. The Baupost Group (the largest KERX shareholder, owning approximately 21.4% of the outstanding KERX c… read more...
Keryx Biopharmaceuticals And Akebia Therapeutics: Was The Reaction To The Merger Announcement Justified?
via: SeekingAlpha at 2018-07-06 13:09:56:000
By Eric Egana and Elle Investments On Thursday, June 28, Keryx Biopharmaceuticals (NASDAQ:KERX) and Akebia Therapeutics (NASDAQ:AKBA) announced they would combine in an all-stock merger. The Baupost Group (the largest KERX shareholder, owning approximately 21.4% of the outstanding KERX c… read more...
Keryx Biopharmaceuticals And Akebia Therapeutics: Was The Reaction To The Merger Announcement Justified?
via: SeekingAlpha at 2018-07-06 13:09:56:000
By Eric Egana and Elle Investments On Thursday, June 28, Keryx Biopharmaceuticals (NASDAQ:KERX) and Akebia Therapeutics (NASDAQ:AKBA) announced they would combine in an all-stock merger. The Baupost Group (the largest KERX shareholder, owning approximately 21.4% of the outstanding KERX c… read more...
Keryx Biopharmaceuticals And Akebia Therapeutics: Was The Reaction To The Merger Announcement Justified?
via: SeekingAlpha at 2018-07-06 13:09:56:000
By Eric Egana and Elle Investments On Thursday, June 28, Keryx Biopharmaceuticals (NASDAQ:KERX) and Akebia Therapeutics (NASDAQ:AKBA) announced they would combine in an all-stock merger. The Baupost Group (the largest KERX shareholder, owning approximately 21.4% of the outstanding KERX c… read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-07-02 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted six newly-hired employees options to purchase an aggregate of 12,050 shares of Akeb… read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-07-02 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted six newly-hired employees options to purchase an aggregate of 12,050 shares of Akeb… read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-07-02 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted six newly-hired employees options to purchase an aggregate of 12,050 shares of Akeb… read more...
WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc.
via: PR Newswire at 2018-06-29 19:12:00:000
NEW YORK , June 29, 2018 /PRNewswire/ --WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Keryx Biopharmaceuticals Inc. ("KERX" or the "Company") (NASDAQ: KERX) in connection with the proposed acquisition of th… read more...
WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc.
via: PR Newswire at 2018-06-29 19:12:00:000
NEW YORK , June 29, 2018 /PRNewswire/ --WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Keryx Biopharmaceuticals Inc. ("KERX" or the "Company") (NASDAQ: KERX) in connection with the proposed acquisition of th… read more...
WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc.
via: PR Newswire at 2018-06-29 19:12:00:000
NEW YORK , June 29, 2018 /PRNewswire/ --WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Keryx Biopharmaceuticals Inc. ("KERX" or the "Company") (NASDAQ: KERX) in connection with the proposed acquisition of th… read more...
Akebia Therapeutics, Inc. (AKBA) Merger & Acquisition Call - Transcript
via: SeekingAlpha at 2018-06-28 23:43:03:000
Akebia Therapeutics, Inc. (AKBA) Merger & Acquisition Call June 28, 2018 8:00 A.M. ET Executives Amy Sullivan - Senior Vice President, Corporate Affairs John Butler - President and Chief Executive Officer, Akebia Therapeutics Jodie Morrison - Interim Chief Executive Officer,… read more...
Akebia Therapeutics, Inc. (AKBA) Merger & Acquisition Call - Transcript
via: SeekingAlpha at 2018-06-28 23:43:03:000
Akebia Therapeutics, Inc. (AKBA) Merger & Acquisition Call June 28, 2018 8:00 A.M. ET Executives Amy Sullivan - Senior Vice President, Corporate Affairs John Butler - President and Chief Executive Officer, Akebia Therapeutics Jodie Morrison - Interim Chief Executive Officer,… read more...
Akebia Therapeutics, Inc. (AKBA) Merger & Acquisition Call - Transcript
via: SeekingAlpha at 2018-06-28 23:43:03:000
Akebia Therapeutics, Inc. (AKBA) Merger & Acquisition Call June 28, 2018 8:00 A.M. ET Executives Amy Sullivan - Senior Vice President, Corporate Affairs John Butler - President and Chief Executive Officer, Akebia Therapeutics Jodie Morrison - Interim Chief Executive Officer,… read more...
Akebia Keryx Merger Investor Presentation
via: SeekingAlpha at 2018-06-28 10:26:10:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Premarket Gainers as of 9:05 am (6/28/2018)
via: SeekingAlpha at 2018-06-28 09:18:07:000
GBR +150% . More news on: New Concept Energy, Inc., PEDEVCO Corp., SAExploration Holdings, Inc., Stocks on the move, Read more … read more...
Akebia Therapeutics, Keryx Biopharma agree to merge
via: SeekingAlpha at 2018-06-28 07:26:05:000
Akebia Therapeutics (NASDAQ: AKBA ) and Keryx Biopharmaceuticals (NASDAQ: KERX ) announce an all-stock merger that will create a company focused on chronic kidney disease, with an implied pro forma equity value of ~$1.3B; shares are halted. More news on: Akebia Therapeutics, Inc., Keryx … read more...
Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease
via: Business Wire at 2018-06-28 07:00:00:000
Expects to Capture Significant Operating and Product Portfolio Synergies, Accelerating Revenue Growth and Creating Shareholder Value Consolidates an FDA-Approved Oral CKD Product and an Investigational, Phase 3 Oral CKD Product Candidate Under Combined Experienced Renal Leadership … read more...
Institutional Top Ideas: EcoR1 Capital
via: SeekingAlpha at 2018-06-12 02:08:54:000
In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...
Institutional Top Ideas: EcoR1 Capital
via: SeekingAlpha at 2018-06-12 02:08:54:000
In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...
Institutional Top Ideas: EcoR1 Capital
via: SeekingAlpha at 2018-06-12 02:08:54:000
In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...
Tricida readies IPO
via: SeekingAlpha at 2018-06-05 13:33:03:000
South San Francisco, CA-based Tricida ( TCDA ) has filed a preliminary prospectus for a $150M IPO. More news on: Tricida, Inc., Keryx Biopharmaceuticals, Inc., Novo Nordisk A/S, Healthcare stocks news, IPOs, Read more … read more...
Tricida readies IPO
via: SeekingAlpha at 2018-06-05 13:33:03:000
South San Francisco, CA-based Tricida ( TCDA ) has filed a preliminary prospectus for a $150M IPO. More news on: Tricida, Inc., Keryx Biopharmaceuticals, Inc., Novo Nordisk A/S, Healthcare stocks news, IPOs, Read more … read more...
Tricida readies IPO
via: SeekingAlpha at 2018-06-05 13:33:03:000
South San Francisco, CA-based Tricida ( TCDA ) has filed a preliminary prospectus for a $150M IPO. More news on: Tricida, Inc., Keryx Biopharmaceuticals, Inc., Novo Nordisk A/S, Healthcare stocks news, IPOs, Read more … read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-06-04 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted four newly-hired employees options to purchase an aggregate of 21,300 shares of Ake… read more...
Akebia Therapeutics to Present at Upcoming Investor Conference
via: Business Wire at 2018-05-15 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that its President and Chief Executive Officer, John P. Butler, will presen… read more...
Akebia Therapeutics to Present at Upcoming Investor Conference
via: Business Wire at 2018-05-15 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that its President and Chief Executive Officer, John P. Butler, will presen… read more...
Akebia Therapeutics to Present at Upcoming Investor Conference
via: Business Wire at 2018-05-15 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that its President and Chief Executive Officer, John P. Butler, will presen… read more...
Akebia Therapeutics to Present at Upcoming Investor Conference
via: Business Wire at 2018-05-15 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that its President and Chief Executive Officer, John P. Butler, will presen… read more...
Akebia Therapeutics to Present at Upcoming Investor Conference
via: Business Wire at 2018-05-15 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that its President and Chief Executive Officer, John P. Butler, will presen… read more...
Akebia Therapeutics to Present at Upcoming Investor Conference
via: Business Wire at 2018-05-15 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that its President and Chief Executive Officer, John P. Butler, will presen… read more...
Akebia beats by $0.11, misses on revenue
via: SeekingAlpha at 2018-05-09 16:48:34:000
Akebia (NASDAQ: AKBA ): Q1 EPS of -$0.48 beats by $0.11 . Revenue of $45.93M (+120.2% Y/Y) misses by $0.2M . Press Release More news on: Akebia Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, read more...
Akebia beats by $0.11, misses on revenue
via: SeekingAlpha at 2018-05-09 16:48:34:000
Akebia (NASDAQ: AKBA ): Q1 EPS of -$0.48 beats by $0.11 . Revenue of $45.93M (+120.2% Y/Y) misses by $0.2M . Press Release More news on: Akebia Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, read more...
Akebia Therapeutics Announces First Quarter 2018 Financial Results
via: Business Wire at 2018-05-09 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced financial results for the first quarter ended March 31, 2018. W… read more...
Akebia Therapeutics Announces First Quarter 2018 Financial Results
via: Business Wire at 2018-05-09 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced financial results for the first quarter ended March 31, 2018. W… read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-05-02 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted five newly-hired employees options to purchase an aggregate of 10,450 shares of Ake… read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-05-02 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted five newly-hired employees options to purchase an aggregate of 10,450 shares of Ake… read more...
Weekly Review: Municipal Bond CEFs
via: SeekingAlpha at 2018-05-02 01:49:21:000
Introduction Over the past few months, most of you have noticed our increased activity in closed-end funds, as the inflow of volatility finally shook them up and created various arbitrage, and directional, opportunities for active traders such as us. Now that these products have our attent… read more...
Weekly Review: Municipal Bond CEFs
via: SeekingAlpha at 2018-05-02 01:49:21:000
Introduction Over the past few months, most of you have noticed our increased activity in closed-end funds, as the inflow of volatility finally shook them up and created various arbitrage, and directional, opportunities for active traders such as us. Now that these products have our attent… read more...
Akebia (AKBA) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
via: SeekingAlpha at 2018-04-10 12:22:34:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia (AKBA) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
via: SeekingAlpha at 2018-04-10 12:22:34:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-04-03 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted 13 newly-hired employees options to purchase an aggregate of 63,000 shares of Akebi… read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-04-03 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted 13 newly-hired employees options to purchase an aggregate of 63,000 shares of Akebi… read more...
Premarket Losers as of 9:05 am (3/23/2018)
via: SeekingAlpha at 2018-03-23 09:08:51:000
PGNX -16% on extension of FDA review of Azedra application. More news on: Progenics Pharmaceuticals Inc., Resonant, Akebia Therapeutics, Inc., Stocks on the move, , Read more … read more...
Premarket Losers as of 9:05 am (3/23/2018)
via: SeekingAlpha at 2018-03-23 09:08:51:000
PGNX -16% on extension of FDA review of Azedra application. More news on: Progenics Pharmaceuticals Inc., Resonant, Akebia Therapeutics, Inc., Stocks on the move, , Read more … read more...
Akebia Therapeutics down 11% on pricing public offering of common stock
via: SeekingAlpha at 2018-03-23 08:19:44:000
Akebia Therapeutics (NASDAQ: AKBA ) prices its public offering of 8.5M shares of common stock at a price of $10.50 per share. Underwriters over-allotment is an additional 1.275M shares. More news on: Akebia Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read mor… read more...
Akebia Therapeutics down 11% on pricing public offering of common stock
via: SeekingAlpha at 2018-03-23 08:19:44:000
Akebia Therapeutics (NASDAQ: AKBA ) prices its public offering of 8.5M shares of common stock at a price of $10.50 per share. Underwriters over-allotment is an additional 1.275M shares. More news on: Akebia Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read mor… read more...
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
via: Business Wire at 2018-03-23 08:00:00:000
Akebia Therapeutics, Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the pricing of an underwritten public offering of 8,500,000 shares of common … read more...
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
via: Business Wire at 2018-03-23 08:00:00:000
Akebia Therapeutics, Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the pricing of an underwritten public offering of 8,500,000 shares of common … read more...
Akebia (AKBA) Presents At BIO CEO & Investor Conference - Slideshow
via: SeekingAlpha at 2018-02-13 13:42:11:000
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more … read more...
Akebia and Otsuka tweak design of late-stage vadadustat studies, marketing approval in Japan may be 2021; shares down 2%
via: SeekingAlpha at 2018-02-12 10:15:31:000
In an update to investors, Akebia Therapeutics ( AKBA -1.6% ) announces that it and commercialization partner Mitsubishi Tanabe Pharma have changed the designs of two Japan-based Phase 3 studies, FO2RWARD and TRILO2GY, evaluating vadadustat in patients with anemia associated with dialysi… read more...
Akebia and Otsuka tweak design of late-stage vadadustat studies, marketing approval in Japan may be 2021; shares down 2%
via: SeekingAlpha at 2018-02-12 10:15:31:000
In an update to investors, Akebia Therapeutics ( AKBA -1.6% ) announces that it and commercialization partner Mitsubishi Tanabe Pharma have changed the designs of two Japan-based Phase 3 studies, FO2RWARD and TRILO2GY, evaluating vadadustat in patients with anemia associated with dialysi… read more...
Akebia Therapeutics Provides Update on Vadadustat Development Program
via: Business Wire at 2018-02-12 07:00:00:000
-- Targets Full Enrollment for INNO 2 VATE and PRO 2 TECT by the End of 2018 -- -- Confirms Expectation of Top-Line Results for INNO 2 VATE and PRO 2 TECT in 2019, Subject to Accrual of MACE Events -- -- Enhances FO 2 RWARD and TRILO 2 GY Study Designs for … read more...
Akebia Therapeutics Provides Update on Vadadustat Development Program
via: Business Wire at 2018-02-12 07:00:00:000
-- Targets Full Enrollment for INNO 2 VATE and PRO 2 TECT by the End of 2018 -- -- Confirms Expectation of Top-Line Results for INNO 2 VATE and PRO 2 TECT in 2019, Subject to Accrual of MACE Events -- -- Enhances FO 2 RWARD and TRILO 2 GY Study Designs for … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Key healthcare events next week (continued)
via: SeekingAlpha at 2018-02-09 12:37:01:000
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...
Akebia Therapeutics to Present at Upcoming February Investor Conferences
via: Business Wire at 2018-02-08 08:00:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at… read more...
Akebia Therapeutics to Present at Upcoming February Investor Conferences
via: Business Wire at 2018-02-08 08:00:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at… read more...
Akebia Therapeutics to Present at Upcoming February Investor Conferences
via: Business Wire at 2018-02-08 08:00:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at… read more...
Akebia Therapeutics to Present at Upcoming February Investor Conferences
via: Business Wire at 2018-02-08 08:00:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at… read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-02-02 16:30:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted nine newly-hired employees options to purchase an aggregate of 53,550 shares of Ake… read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-02-02 16:30:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted nine newly-hired employees options to purchase an aggregate of 53,550 shares of Ake… read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-02-02 16:30:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted nine newly-hired employees options to purchase an aggregate of 53,550 shares of Ake… read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-02-02 16:30:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted nine newly-hired employees options to purchase an aggregate of 53,550 shares of Ake… read more...
Your Daily Pharma Scoop: ChemoCentryx Surges, Akebia Gets Positive News, Atara Prices Public Offering
via: SeekingAlpha at 2018-01-05 01:36:56:000
Analysis of top Seeking Alpha coverage: ChemoCentryx Today we will discuss an update from ChemoCentryx ( CCXI ), which sent shares more than 30% higher in intra-day trading. ChemoCentryx is primarily focused on orphan and rare diseases. The companys lead product candidate is Avac… read more...
Akebia's vadadustat shows positive results in Japan-based anemia study
via: SeekingAlpha at 2018-01-04 10:39:20:000
A Phase 2 clinical trial conducted by Akebia Therapeutics ( AKBA +0.6% ) commercialization partner Mitsubishi Tanabe Pharma assessing vadadustat in Japanese patients with anemia associated with dialysis-dependent chronic kidney disease (DD-CKD) met its primary endpoint . The results were … read more...
Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease
via: Business Wire at 2018-01-04 07:00:00:000
-- Data Consistent with Findings from Previous Studies -- -- Phase 3 Study of Non-Dialysis Patients in Japan Ongoing; Phase 3 Studies of Dialysis Patients to Begin in 2018 -- Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative t… read more...
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2018-01-02 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the Company granted six newly-hired employees options to purchase an a… read more...
Your Daily Pharma Scoop: Valeant Still Risky, Onconova Signs Agreement, Array Biopharma Announces Collaboration
via: SeekingAlpha at 2017-12-20 05:46:56:000
Content Analysis of coverage: VRX Stocks in the news: ONTX, RGNX, ARRY Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Trade Idea for the Day (for TPT subscribers only) Subscriber Questions & Ans… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2017-12-19 08:56:33:000
Sucampo Pharmaceuticals (NASDAQ: SCMP ) initiated with Buy rating and $43 (157% upside) price target by Nomura Securities. Shares up 4% premarket on light volume. More news on: Sucampo Pharmaceuticals, Inc., Akebia Therapeutics, Inc., Novavax, Inc., Healthcare stocks news, Stoc… read more...
Your Daily Pharma Scoop: Celgene Upside, Erytech Tumbles, Novartis Neulasta Biosimilar
via: SeekingAlpha at 2017-12-11 07:00:00:000
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea… read more...
Akebia Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
via: Business Wire at 2017-12-01 16:05:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the Company granted three newly-hired employees options to purchase an… read more...
Your Daily Pharma Scoop: A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tumbles
via: SeekingAlpha at 2017-11-16 14:35:00:000
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Sanofi Today we will discuss an art… read more...
Akebia Therapeutics to Participate in Upcoming Investor Conferences
via: Business Wire at 2017-11-16 08:00:00:000
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participat… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|